Federal report finds high-cost drug sales doubled between 2006, 2016
The federal health minister tabled a report from the Patented Medicine Prices Review Board (PMPRB) which shows that drugs with an annual per beneficiary cost of at least $10,000 accounted for 40% of patented drug sales in 2016. Furthermore, the cost